CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

EMA News
Original article

EMA fast tracks review of a medicine for metastatic pancreatic cancer

RegulatorydaraxonrasibPositive
AI Analysis

Summary

The EMA's CHMP has initiated a phased review of daraxonrasib for metastatic pancreatic cancer, representing a regulatory milestone for the treatment candidate.

Outcome Details

EMA CHMP started phased review

Importance:6/10
Sentiment:
0.60
EMAfast track reviewphased reviewpancreatic cancerregulatory milestone
Related Companies

Read the original article

Published by EMA News on July 7, 2026 12:30 PM

Read Original